Scolaris Content Display Scolaris Content Display

Cochrane Database of Systematic Reviews

Agentes hipolipemiantes para el síndrome nefrótico

Información

DOI:
https://doi.org/10.1002/14651858.CD005425.pub2Copiar DOI
Base de datos:
  1. Cochrane Database of Systematic Reviews
Versión publicada:
  1. 10 diciembre 2013see what's new
Tipo:
  1. Intervention
Etapa:
  1. Review
Grupo Editorial Cochrane:

  1. Grupo Cochrane de Riñón y trasplante

Copyright:
  1. Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Cifras del artículo

Altmetric:

Citado por:

Citado 0 veces por enlace Crossref Cited-by

Contraer

Autores

  • Xiangyu Kong

    Department of Epidemiology and Biostatistics, School of Public Health, Chengdu Medical College, Chengdu, China

  • Hao Yuan

    Department of Evidence‐Based Medicine and Clinical Epidemiology, West China Hospital, Sichuan University, Chengdu, China

  • Junming Fan

    Department of Nephrology, Luzhou Medical College, Luzhou, China

  • Zi Li

    Department of Nephrology, West China Hospital, Sichuan University, Chengdu, China

  • Taixiang Wu

    Correspondencia a: Chinese Clinical Trial Registry, Chinese Ethics Committee of Registering Clinical Trials, West China Hospital, Sichuan University, Chengdu, China

    [email protected]

  • Lanhui Jiang

    Chinese Evidence‐Based Medicine Centre, West China Hospital, Sichuan University, Chengdu, China

Contributions of authors

  • Kong Xiangyu: searching for studies, studies selection, quality assessment of studies, data extraction, data analysis.

  • Yuan Hao: searching for studies, studies selection, quality assessment of studies, data extraction, data analysis.

  • Wu Taixiang: protocol development, quality assessment of studies, data extraction, data analysis, critical revision of protocol.

  • Fan Junming: quality assessment of studies, data analysis, critical revision of protocol

  • Li Zi: quality assessment of studies, data analysis, critical revision of protocol

  • Jiang Lanhui: quality assessment of studies, checking English writing.

Sources of support

Internal sources

  • Chinese Cochrane Centre, West China Hospital of Sichuan University, China.

External sources

  • No sources of support supplied

Declarations of interest

None known.

Acknowledgements

We thank the Cochrane Renal Group for their assistance in the development of our search strategies, and the referees for their comments and feedback during the preparation of this review.

Version history

Published

Title

Stage

Authors

Version

2013 Dec 10

Lipid‐lowering agents for nephrotic syndrome

Review

Xiangyu Kong, Hao Yuan, Junming Fan, Zi Li, Taixiang Wu, Lanhui Jiang

https://doi.org/10.1002/14651858.CD005425.pub2

2005 Jul 20

Lipid‐lowering agents for nephrotic syndrome

Protocol

Junming Fan, Zi Li, Taixiang Wu, Haiyan Chen

https://doi.org/10.1002/14651858.CD005425

Differences between protocol and review

  1. The Cochrane Renal Group’s Specialised Register includes weekly Ovid MEDLINE AutoAlerts and regular searching of Ovid SP EMBASE, we did not search MEDLINE or EMBASE for this review.

  2. In compliance with current Cochrane methodology, the quality checklist indicated in the protocol was replaced by risk of bias assessment.

Keywords

MeSH

Medical Subject Headings (MeSH) Keywords

Medical Subject Headings Check Words

Adult; Child; Humans;

PICO

Population
Intervention
Comparison
Outcome

El uso y la enseñanza del modelo PICO están muy extendidos en el ámbito de la atención sanitaria basada en la evidencia para formular preguntas y estrategias de búsqueda y para caracterizar estudios o metanálisis clínicos. PICO son las siglas en inglés de cuatro posibles componentes de una pregunta de investigación: paciente, población o problema; intervención; comparación; desenlace (outcome).

Para saber más sobre el uso del modelo PICO, puede consultar el Manual Cochrane.

Study selection flow diagram
Figuras y tablas -
Figure 1

Study selection flow diagram

Ir a la figura de la revisiónAbrir en una pestaña nueva

Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies
Figuras y tablas -
Figure 2

Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies

Ir a la figura de la revisiónAbrir en una pestaña nueva

Risk of bias summary: review authors' judgements about each risk of bias item for each included study
Figuras y tablas -
Figure 3

Risk of bias summary: review authors' judgements about each risk of bias item for each included study

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Lipid‐lowering agents versus placebo or no treatment, Outcome 1 Total cholesterol.
Figuras y tablas -
Analysis 1.1

Comparison 1 Lipid‐lowering agents versus placebo or no treatment, Outcome 1 Total cholesterol.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Lipid‐lowering agents versus placebo or no treatment, Outcome 2 LDL cholesterol.
Figuras y tablas -
Analysis 1.2

Comparison 1 Lipid‐lowering agents versus placebo or no treatment, Outcome 2 LDL cholesterol.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Lipid‐lowering agents versus placebo or no treatment, Outcome 3 HDL cholesterol.
Figuras y tablas -
Analysis 1.3

Comparison 1 Lipid‐lowering agents versus placebo or no treatment, Outcome 3 HDL cholesterol.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Lipid‐lowering agents versus placebo or no treatment, Outcome 4 Triglyceride.
Figuras y tablas -
Analysis 1.4

Comparison 1 Lipid‐lowering agents versus placebo or no treatment, Outcome 4 Triglyceride.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Lipid‐lowering agents versus placebo or no treatment, Outcome 5 Serum creatinine.
Figuras y tablas -
Analysis 1.5

Comparison 1 Lipid‐lowering agents versus placebo or no treatment, Outcome 5 Serum creatinine.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Lipid‐lowering agents versus placebo or no treatment, Outcome 6 Blood urea nitrogen.
Figuras y tablas -
Analysis 1.6

Comparison 1 Lipid‐lowering agents versus placebo or no treatment, Outcome 6 Blood urea nitrogen.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Lipid‐lowering agents versus placebo or no treatment, Outcome 7 Proteinuria.
Figuras y tablas -
Analysis 1.7

Comparison 1 Lipid‐lowering agents versus placebo or no treatment, Outcome 7 Proteinuria.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Lipid‐lowering agents versus placebo or no treatment, Outcome 8 Serum albumin.
Figuras y tablas -
Analysis 1.8

Comparison 1 Lipid‐lowering agents versus placebo or no treatment, Outcome 8 Serum albumin.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Lipid‐lowering agents versus placebo or no treatment, Outcome 9 Total serum protein.
Figuras y tablas -
Analysis 1.9

Comparison 1 Lipid‐lowering agents versus placebo or no treatment, Outcome 9 Total serum protein.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Lipid‐lowering agents versus placebo or no treatment, Outcome 10 Apolipoprotein A.
Figuras y tablas -
Analysis 1.10

Comparison 1 Lipid‐lowering agents versus placebo or no treatment, Outcome 10 Apolipoprotein A.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Lipid‐lowering agents versus placebo or no treatment, Outcome 11 Apolipoprotein B.
Figuras y tablas -
Analysis 1.11

Comparison 1 Lipid‐lowering agents versus placebo or no treatment, Outcome 11 Apolipoprotein B.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Lipid‐lowering agents versus placebo or no treatment, Outcome 12 Elevated liver enzymes.
Figuras y tablas -
Analysis 1.12

Comparison 1 Lipid‐lowering agents versus placebo or no treatment, Outcome 12 Elevated liver enzymes.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Lipid‐lowering agents versus placebo or no treatment, Outcome 13 Alanine aminotransferase.
Figuras y tablas -
Analysis 1.13

Comparison 1 Lipid‐lowering agents versus placebo or no treatment, Outcome 13 Alanine aminotransferase.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Lipid‐lowering agents versus placebo or no treatment, Outcome 14 Aspartate aminotransferase.
Figuras y tablas -
Analysis 1.14

Comparison 1 Lipid‐lowering agents versus placebo or no treatment, Outcome 14 Aspartate aminotransferase.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Lipid‐lowering agents versus placebo or no treatment, Outcome 15 Creatine phosphokinase.
Figuras y tablas -
Analysis 1.15

Comparison 1 Lipid‐lowering agents versus placebo or no treatment, Outcome 15 Creatine phosphokinase.

Ir a la figura de la revisiónAbrir en una pestaña nueva
Comparison 1. Lipid‐lowering agents versus placebo or no treatment

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Total cholesterol Show forest plot

3

Mean Difference (IV, Random, 95% CI)

Subtotals only

1.1 Statins (3 months)

2

92

Mean Difference (IV, Random, 95% CI)

‐53.04 [‐159.53, 53.45]

1.2 Statins (6 months)

1

52

Mean Difference (IV, Random, 95% CI)

‐45.0 [‐144.57, 54.57]

1.3 Statins (1 year)

1

52

Mean Difference (IV, Random, 95% CI)

‐46.0 [‐144.26, 52.26]

1.4 Fibrates

1

12

Mean Difference (IV, Random, 95% CI)

42.0 [‐33.63, 117.63]

2 LDL cholesterol Show forest plot

2

Mean Difference (IV, Random, 95% CI)

Totals not selected

2.1 Statins

1

Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

2.2 Fibrates

1

Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

3 HDL cholesterol Show forest plot

2

Mean Difference (IV, Random, 95% CI)

Totals not selected

3.1 Statins

1

Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

3.2 Fibrates

1

Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

4 Triglyceride Show forest plot

2

Mean Difference (IV, Random, 95% CI)

Totals not selected

4.1 Statins

1

Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

4.2 Fibrates

1

Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

5 Serum creatinine Show forest plot

3

Mean Difference (IV, Random, 95% CI)

Totals not selected

5.1 Statins (3 months)

1

Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

5.2 Statins (6 months)

1

Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

5.3 Statins (1 year)

1

Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

5.4 Fibrates

1

Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

6 Blood urea nitrogen Show forest plot

2

Mean Difference (IV, Random, 95% CI)

Totals not selected

6.1 Statins

1

Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

6.2 Fibrates

1

Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

7 Proteinuria Show forest plot

2

Std. Mean Difference (IV, Random, 95% CI)

Totals not selected

7.1 Statins

1

Std. Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

7.2 Fibrates

1

Std. Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

8 Serum albumin Show forest plot

2

Mean Difference (IV, Random, 95% CI)

Totals not selected

8.1 Statins (6 months)

1

Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

8.2 Statins (1 year)

1

Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

8.3 Fibrates

1

Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

9 Total serum protein Show forest plot

1

Mean Difference (IV, Random, 95% CI)

Totals not selected

9.1 Fibrates

1

Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

10 Apolipoprotein A Show forest plot

1

Mean Difference (IV, Random, 95% CI)

Totals not selected

10.1 Fibrates

1

Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

11 Apolipoprotein B Show forest plot

1

Mean Difference (IV, Random, 95% CI)

Totals not selected

11.1 Fibrates

1

Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

12 Elevated liver enzymes Show forest plot

1

Risk Ratio (M‐H, Random, 95% CI)

Totals not selected

12.1 Statins

1

Risk Ratio (M‐H, Random, 95% CI)

0.0 [0.0, 0.0]

13 Alanine aminotransferase Show forest plot

1

Mean Difference (IV, Random, 95% CI)

Totals not selected

13.1 Fibrates

1

Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

14 Aspartate aminotransferase Show forest plot

1

Mean Difference (IV, Random, 95% CI)

Totals not selected

14.1 Fibrates

1

Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

15 Creatine phosphokinase Show forest plot

1

Mean Difference (IV, Random, 95% CI)

Totals not selected

15.1 Fibrates

1

Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]
Figuras y tablas -
Comparison 1. Lipid‐lowering agents versus placebo or no treatment
Ir a la tabla de la revisión